MacroGenics
MGNX
A$2.42
Share price
-5.39%
Change (1 day)
-71.00%
Change (1 year)
Categories
Revenue for MacroGenics (MGNX)
Revenue in 2025 (TTM): A$0.22 Billion
According to MacroGenics's latest financial reports the company's current revenue (TTM 
) is A$0.23 Billion. In 2024 the company made a revenue of A$0.23 Billion an increase over the revenue in the year 2023 that were of A$83.94 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MacroGenics from 2013 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | A$0.22 B | -5.28% |
| 2024 | A$0.23 B | 184.09% |
| 2023 | A$83.94 M | -61.81% |
| 2022 | A$0.21 B | 109.38% |
| 2021 | A$0.10 B | -17.43% |
| 2020 | A$0.12 B | 43.52% |
| 2019 | A$88.58 M | 3.8% |
| 2018 | A$85.34 M | -57.76% |
| 2017 | A$0.20 B | 58.52% |
| 2016 | A$0.12 B | -7.93% |
| 2015 | A$0.13 B | 139.72% |
| 2014 | A$57.75 M | -9.23% |
| 2013 | A$63.62 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | A$0.22 B | -5.23% | 🇺🇸 USA |
 Pfizer PFE | A$95.85 B | 40,878.96% | 🇺🇸 USA |
 Merck MRK | A$98.09 B | 41,836.14% | 🇺🇸 USA |
 Gilead Sciences GILD | A$44.09 B | 18,750.99% | 🇺🇸 USA |
 Amgen AMGN | A$52.36 B | 22,288.42% | 🇺🇸 USA |
 Eli Lilly LLY | A$75.20 B | 32,048.64% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$73.10 B | 31,151.68% | 🇺🇸 USA |